Veloxis Pharmaceuticals announces financial results for the first three months of 2014 - KAUZ-TV: Newschannel 6 Now | Wichita Falls, TX

Veloxis Pharmaceuticals announces financial results for the first three months of 2014

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Veloxis Pharmaceuticals

HORSHOLM, Denmark, May 14, 2014 /PRNewswire/ --

Highlights:

  • The U.S. Food and Drug Administration (FDA) has accepted for standard review the company's New Drug Application (NDA) for Envarsus® for the prevention of organ rejection in adult kidney transplant patients. The FDA has set a target review date under the Prescription Drug User Fee Act (PDUFA) of October 30, 2014.
  • The Company has previously reported that the MAA for Envarsus® had been accepted by the European Medicines Agency (EMA). A CHMP opinion is expected in 2Q 2014 and regulatory action on the application is expected in 3Q 2014.
  • Veloxis reported a net loss of DKK 20.0 million for the first quarter of 2014 compared to a net loss of DKK 35.7 million for the same period in 2013. The reported net loss is in line with expectations and the financial outlook for 2014 is maintained.
  • For the first quarter of 2014, Veloxis' research and development costs amounted to DKK 26.6 million compared to DKK 38.9 million during the same period in 2013.
  • On 31 March, 2014, Veloxis had cash and cash equivalents of DKK 296.2 million.

Outlook for 2014

Veloxis maintains its 2014 outlook with an operating loss of DKK 60-90 million and a net loss of DKK 55-85 million for the financial year 2014.

As at 31 March 2014, the Company's cash position equaled DKK 296.2 million, and as at 31 December 2014, the Company's cash position is expected to be in the range of DKK 230-270 million.

Conference call

A conference call will be held tomorrow, 15 May, 2014 at 2:00 PM CET (Denmark); 1:00 PM BST (London), 8:00 AM EDT (New York).

To access the live conference call, please dial one of the following numbers:
+45 32 72 80 18 (Denmark)
+44 (0) 1452 555 131 (UK)
+1 866 682 8490 (USA)
Access code 35440957

Following the conference call, a recording will be available on the company's website http://www.veloxis.com.  

Research & development update
Envarsus® in kidney transplant patients
Veloxis has conducted two Phase III studies of Envarsus® in kidney transplant recipients as the basis for its development programme for Envarsus® as a once-daily agent for the prophylaxis of organ rejection in kidney transplantation. The first of these studies, the 3001 Study, was a non-inferiority study performed in 326 stable kidney transplant recipients, and was successfully completed in 2011, meeting its primary efficacy and safety endpoints when compared to Prograf® (tacrolimus, Astellas Pharma Inc.). The second study, Study 3002 was a randomized, double-blind, multicenter study that compared once-daily Envarsus® against twice-daily Prograf® in 543 de novo adult kidney transplant patients and met its primary efficacy and primary safety endpoints. The primary endpoint of the study was a composite endpoint of treatment failure (biopsy-proven acute rejection, graft failure, loss to follow up or death) that was evaluated after a 12-month treatment period to demonstrate the non-inferiority of Envarsus® compared to Prograf®. The treatment failure rate for Envarsus® was 18.3% compared to 19.6% for Prograf®, and the difference between the treatments was well within the 10% pre-specified non-inferiority margin. The primary safety analyses were the differences between Envarsus® and Prograf® treatment groups at Month 12 (Day 360) with respect to the incidence of adverse events (AEs) and the incidence of predefined potentially clinically significant laboratory measures including: fasting plasma glucose; platelet count; white blood cell (WBC) count; aminotransaminases; total cholesterol; low density lipoprotein (LDL) cholesterol; triglycerides; and estimated glomerular filtration rate (eGFR). In all instances, there were no statistically significant differences between the two treatments. Specifically, renal function was similar between the two groups at 12 months, as was the incidence of malignancy, infections and new onset diabetes during this period. Patients are participating in a 12-month extension period on treatment for follow-up safety and efficacy assessments.

In addition to the pivotal Phase III studies, Veloxis is conducting a series of Phase IIIb/IV studies to further evaluate potential differences in clinical profile provided by Envarsus®' unique PK profile. The first study is the STRATO (Switching kidney TRAnsplant patients with Tremor to LCP-tacrO) study of Envarsus® in kidney transplant recipients experiencing drug-induced tremors. The STRATO study was designed to explore whether a conversion of patients who have symptomatic tremor from treatment with standard immediate release twice-daily tacrolimus capsules to extended release once-daily Envarsus® tablets leads to a measurable improvement in tremor. Results from this study demonstrated that patients switched to Envarsus® demonstrated a statistically significant improvement in hand tremors based on improvement in the FTM Tremor rating scale. Additionally, both the patient- and physician-reported global assessments demonstrated significant overall improvements following the switch to Envarsus®.

Additionally, the ASERTAA (A Study of Extended Release Tacrolimus in African-Americans) Phase IIIb study of Envarsus® in kidney transplant recipients is ongoing. The ASERTAA study is designed to compare the pharmacokinetics of Envarsus® given once-daily to generic twice daily tacrolimus capsules in stable African-American renal transplant patients. Results from this study are anticipated to be available in 2015.

Envarsus® Regulatory Strategy
On 29 April, 2013 a Marketing Authorization Application (MAA) was submitted by Veloxis to the European Medicines Agency (EMA) seeking approval to market Envarsus® for the prevention of organ rejection in transplant patients in the European Union. The MAA submission was based on the favourable results of the Envarsus® Phase III 3001 Study in stable kidney transplant patients and data from an extensive Phase I and II clinical programme and has been accepted for review by the EMA. The review of the MAA is on-going and Veloxis expects to receive a decision on the application in 3Q 2014.

Veloxis submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of Envarsus® in the US for the prevention of organ rejection in kidney transplant recipients on December 30, 2013. The FDA has accepted for standard review the NDA for Envarsus® and has set a target review date under the Prescription Drug User Fee Act (PDUFA) of October 30, 2014.

In addition, the FDA granted Envarsus® Orphan Drug status for prophylaxis of organ rejection in patients receiving allogeneic kidney transplants. The designation is to encourage the development of drugs that may provide significant benefit to patients suffering from rare diseases.

Financial Highlights











Q1

Q1

Year



2014

2013

2013



DKK'000

DKK'000

DKK'000






Income Statement




Revenue

12,206

6,868

38,148

Research and development costs

(26,624)

(38,947)

(146,512)

Administrative expenses

(7,749)

(7,777)

(27,771)

Operating loss

(22,167)

(39,856)

(136,135)

Net financial income / (expenses)

677

3,907

(4,426)

Loss before tax

(21,490)

(35,949)

(140,561)

Tax for the period

1,494

244

1,250

Net loss for the period

(19,996)

(35,704)

(139,311)






Balance Sheet




Cash and cash equivalents

296,237

456,216

328,652

Total assets

305,373

465,939

348,863

Share capital

166,252

166,057

166,057

Total equity

261,538

377,276

279,042

Investment in property, plant and equipment

285

-

1,055






Cash Flow Statement




Cash flow from operating activities

(33,550)

(45,125)

(157,747)

Cash flow from investing activities

(285)

-

(1,055)

Cash flow from financing activities

684

48

(3,227)

Cash and cash equivalents at period end

296,237

456,216

328,652






Financial Ratios




Basic and diluted EPS

(0.01)

(0.02)

(0.08)

Weighted average number of shares

1,660,833,074

1,659,683,537

1,660,353,248

Average number of employees (FTEs)

22

29

26

Assets/equity

1.17

1.24

1.25

The interim report has not been audited or reviewed by the company's independent auditors.

Revenue
For the first quarter of 2014 Veloxis recognized deferred revenue of DKK 12.2 million as revenue compared to DKK 6.9 million in the same period of 2013. Deferred revenue consist of up-front and milestone payments under Veloxis' distribution agreement with Chiesi Farmaceutici S.p.A. and is recognized in the income statement based on planned development periods.

Research and development costs
For the first quarter of 2014, Veloxis' research and development costs amounted to DKK 26.6 million compared to DKK 38.9 million during the same period in 2013. Research and development costs are mainly attributable to the phase III trial in Envarsus® (de novo patients, Study 3002). The reduction in cost is associated with the overall reduction in study activity as the study is approaching finalization.

Administrative expenses
For the first quarter of 2014, Veloxis' administrative cost amounted to DKK 7.7 million compared to DKK 7.8 million during the same period in 2013.

Compensation costs
For the first quarter of 2014, a total of DKK 1.8 million was recognized as share-based compensation. The cost is included in R&D and G&A. The comparable cost for 2013 was DKK 2.9 million.

In the first quarter of 2014, a total of 4,382,843 warrants have been cancelled, a total of 1,954,857 warrants have been exercised at an exercise price of DKK 0.35, and a total of 15,647,781 warrants were granted to Executive Management at a strike price of DKK 0.95, a total of 6,408,249 warrants at a strike price of DKK 0.95 was granted to Senior Management and a total of 911,726 warrants at a strike price of DKK 0.95 was granted to other employees.

As of 31 March, 2014, there were a total of 99,147,481 warrants outstanding at an average strike price of DKK 0.73. Members of the Board of Directors held 589,584 warrants at an average strike price of DKK 1.43. Members of the Executive Management held 61,279,081 warrants at an average strike price of DKK 0.51, while other current and former employees held 37,278,816 warrants at an average strike price of DKK 1.08.

Please refer to Veloxis' latest annual report for additional details on the Company's warrant programs.

Operating loss
Veloxis' operating loss for the first quarter of 2014 was DKK 22.2 million compared to DKK 39.8 million in the corresponding period of 2013.

Financial income
During the first quarter of 2014, the Company recognized net financial income of DKK 0.7 million compared to net financial income of DKK 3.9 million in the corresponding period of 2013. The income is mainly due to unrealized currency gain following a slight increase in the USD / DKK currency rate during the first quarter of 2014.

Net loss
Veloxis' net loss for the first quarter of 2014 was DKK 20.0 million compared to DKK 35.7 million in the corresponding period of 2013.

Cash flow
As per 31 March, 2014, the balance sheet reflects cash and cash equivalents of DKK 296.2 million compared to DKK 328.7 million as per 31 December, 2013. This represents a decrease of DKK 32.5 million primarily related to the Company's operating activities for the period.

Balance sheet
As per 31 March, 2014, total assets were DKK 305.4 million compared to DKK 348.9 million at the end of 2013.

Shareholders' equity equalled DKK 261.5 million as of 31 March, 2014, compared to DKK 279.0 million at the end of 2013.

Significant risks and uncertainties
Veloxis faces a number of risks and uncertainties related to operations, research and development, commercial and financial activities. For further information about risks and uncertainties, we refer to the Annual Report for 2013. As of the date of this Interim Report, there have been no significant changes to Veloxis' overall risk profile since the publication of the Annual Report for 2013.

For more information, please contact:



John D. Weinberg                                

       Johnny Stilou

EVP, Chief Operating Officer                 

       EVP, Chief Financial Officer

Mobile: +1 732 321 3208                       

       Mobile: +45 21 227 227

Email: jdw@veloxis.com                        

       Email: jst@veloxis.com  

The forward looking statements and targets contained herein are based on the current view and assumptions of the Executive Management and the Board of Directors of Veloxis Pharmaceuticals A/S. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. Veloxis Pharmaceuticals A/S expressly disclaim any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this interim report to reflect any change in events, conditions, assumptions, or circulations on which any such statements are based unless  required by applicable law.

About Envarsus® and tacrolimus
Tacrolimus is a leading immunosuppression drug used for the prevention of transplant allograft rejection after transplantation. Envarsus® is an investigational drug that is being developed as a once-daily tablet version of tacrolimus with improved bioavailability, consistent pharmacokinetic performance and reduced peak-to-trough variability when compared to currently approved tacrolimus products. Transplant patients need to maintain a minimum blood level of tacrolimus for the prevention of transplant allograft rejection, but excessive levels may increase the risk of serious side effects such as nephrotoxicity, tremor, diabetes, high blood pressure, and opportunistic infections. Therefore, tacrolimus levels need to be managed carefully, and transplant patients are typically obliged to make frequent visits to the hospital for monitoring and dose adjustments after receiving a new organ.

About Veloxis Pharmaceuticals
Based in Horsholm, Denmark, with an office in New Jersey, Veloxis is a specialty pharmaceutical company. The company's lead product candidate is Envarsus® for immunosuppression, specifically organ transplantation. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability at low scale up costs. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market that is commercialized through partner Santarus, Inc. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.

For further information, please visit http://www.veloxis.com.

Executive Management's and the Board of Directors' Statement on the Interim Report

The Executive Management and the Board of Directors have considered and adopted the Interim Report for the 3 months ended 31 March 2014 of Veloxis Pharmaceuticals A/S.

The Interim Report is prepared in accordance with International Accounting Standard No. 34 (IAS 34), "Interim Financial Reporting" and additional Danish disclosure requirements for financial reporting of listed companies.

We consider the applied accounting policies to be appropriate and, in our opinion, the Interim Report gives a true and fair view of the assets and liabilities, financial position, results of the operation and cash flow of the group for the period under review. Furthermore, in our opinion the management review includes a fair review of the development and performance of the business and the financial position of the group, together with a description of the material risks and uncertainties the group faces.

Horsholm, 14 May, 2014

Executive Management




Dr. William J. Polvino                       

Johnny Stilou   

President & CEO                           

Executive Vice President & CFO                          



Board of Directors




Kim Bjornstrup                

Thomas Dyrberg                                                      

(Chairman)                    

(Deputy Chairman)



Anders Gotzsche                    

Mette Kirstine Agger                                              

         


Financial Highlights







Quarterly Numbers in DKK

















Q1


Q4

Q3

Q2

Q1



2014


2013

2013

2013

2013



DKK'000


DKK'000

DKK'000

DKK'000

DKK'000









Income Statement







Revenue

12,206


12,206

12,206

6,868

6,868

Research and development costs

(26,624)


(29,546)

(35,247)

(42,772)

(38,947)

Administrative expenses

(7,749)


(6,457)

(6,703)

(6,834)

(7,777)

Operating loss

(22,167)


(23,797)

(29,744)

(42,738)

(39,856)

Net financial income / (expenses)

677


(1,425)

(4,655)

(2,253)

3,907

Loss before tax

(21,490)


(25,222)

(34,399)

(44,991)

(35,949)

Tax for the period

1,494


522

242

241

244

Net loss for the period

(19,996)


(24,700)

(34,157)

(44,750)

(35,704)









Balance Sheet







Cash and cash equivalents

296,237


328,652

380,179

399,743

456,216

Total assets

305,373


348,863

388,982

409,371

465,939

Share capital

166,252


166,057

166,057

166,057

166,057

Total equity

261,538


279,042

302,307

334,686

377,276

Investment in property, plant and equipment

285


1,055

-

-

-









Cash Flow Statement







Cash flow from operating activities

(33,550)


(47,417)

(14,040)

(51,165)

(45,125)

Cash flow from investing activities

(285)


(1,055)

-

-

-

Cash flow from financing activities

684


(319)

(401)

(2,555)

48

Cash and cash equivalents at period end

296,237


328,652

380,179

399,743

456,216









Financial Ratios







Basic and diluted EPS

(0.01)


(0.01)

(0.02)

(0.03)

(0.02)

Weighted average number of shares

1,660,833,074


1,660,572,426

1,660,572,426

1,660,572,426

1,659,683,537

Average number of employees (FTEs)

22


23

26

27

29

Assets/equity

1.17


1.25

1.29

1.22

1.24

 

 


Income statement and statement of comprehensive income



Income Statement

Consolidated






(DKK'000)

Q1

Q1

Year



2014

2013

2013






Revenue

12,206

6,868

38,148

Research and development costs

(26,624)

(38,947)

(146,512)

Administrative expenses

(7,749)

(7,777)

(27,771)






Operating loss

(22,167)

(39,856)

(136,135)






Financial income

3,191

8,872

1,243

Financial expenses

(2,514)

(4,965)

(5,669)






Loss before tax

(21,490)

(35,949)

(140,561)






Tax for the period

1,494

244

1,250






Net loss for the period

(19,996)

(35,704)

(139,311)





















Basic and diluted EPS

(0.01)

(0.02)

(0.08)






Weighted average number of shares

1,660,833,074

1,659,683,537

1,660,353,248





















Statements of comprehensive income

Consolidated






(DKK'000)

Q1

Q1

Year



2014

2013

2013






Net loss for the period

(19,996)

(35,704)

(139,311)

  Other comprehensive income:




  Items that may be subsequently reclassified




  to profit or loss:




  Currency translation differences, net of tax

26

(128)

(390)






  Other comprehensive income for the period

26

(128)

(390)






Total comprehensive income for the period

(19,970)

(35,832)

(139,701)

 

 


Balance sheet



Assets




Consolidated











(DKK'000)


31 Mar.


31 Mar.


31 Dec.




2014


2013


2013









Patent rights and software


468


2,103


494









Intangible assets


468


2,103


494

















Property, plant and equipment


3,442


2,814


3,333

Leasehold improvements


-


79


-









Property, plant and equipment


3,442


2,893


3,333









Non-current assets


3,910


4,996


3,827

















Other receivables


4,350


3,267


15,170

Prepayments


876


1,460


1,214









Receivables


5,226


4,727


16,384









Cash


296,237


456,216


328,652









Cash and cash equivalents


296,237


456,216


328,652









Current assets


301,463


460,943


345,036









Assets


305,373


465,939


348,863

 

 


Balance sheet



Equity & Liabilities




Consolidated











(DKK'000)


31 Mar.


31 Mar.


31 Dec.




2014


2013


2013









Share capital


166,252


166,057


166,057

Special reserve


407,289


407,289


407,289

Translation reserves


1,994


2,230


1,968

Retained earnings/loss


(313,997)


(198,300)


(296,272)









Equity


261,538


377,276


279,042









Finance lease


-


3,275


-

Trade payables


8,250


20,448


13,026

Deferred revenue


24,412


41,208


36,617

Other payables


11,173


23,732


20,178









Current liabilities


43,835


88,663


69,821









Liabilities


43,835


88,663


69,821









Equity and liabilities


305,373


465,939


348,863

 

 


Cash flow statements



Cash Flow Statement

Consolidated






(DKK'000)

Q1

Q1

Year



2014

2013

2013






Operating loss

(22,167)

(39,856)

(136,135)






Share-based payment

1,782

2,933

8,568

Depreciation and amortization

202

340

1,315

Write-down

-

-

1,243

Changes in working capital

(13,365)

(8,504)

(35,294)






Cash flow from operating activities before interest

(33,548)

(45,087)

(160,303)






Interest received

-

48

1,243

Interest paid

-

(18)

(39)

Corporate tax received

-

-

1,352

Corporate tax paid

(2)

(68)

-






Cash flow from operating activities

(33,550)

(45,125)

(157,747)











Purchase of property, plant and equipment

(285)

-

(1,055)






Cash flow from investing activities

(285)

-

(1,055)











Installments on bank borrowings and finance lease

-

(389)

(3,665)

Proceeds from issuance of shares, net

684

437

438






Cash flow from financing activities

684

48

(3,227)











Increase/(decrease) in cash

(33,151)

(45,077)

(162,029)

Cash at beginning of period

328,652

496,834

496,834

Exchange gains/(losses) on cash

736

4,459

(6,153)






Cash at end of period

296,237

456,216

328,652

 

 

Statement of changes in equity






Consolidated Equity











Number of
Shares


Share
Capital

Share
Premium

Special
Reserves

Translation
Reserves

Retained
Earnings

Total





DKK'000

DKK'000

DKK'000

DKK'000

DKK'000

DKK'000











Equity as of 1 Jan. 2013

1,659,322,426


165,932

-

407,289

2,358

(165,842)

409,737











Net loss for the year







(35,704)

(35,704)

Other comprehensive income for the year





(128)


(128)

Total comprehensive income





(128)

(35,704)

(35,832)











Warrant exercises

1,250,000


125

313




438

Share-based payment







2,933

2,933

Transfer of retained earnings



(313)



313

-











Equity as of 31 Mar. 2013

1,660,572,426


166,057

-

407,289

2,230

(198,300)

377,276











Net loss for the year







(103,606)

(103,606)

Other comprehensive income for the year





(262)


(262)

Total comprehensive income





(262)

(103,606)

(103,868)











Share-based payment







5,634

5,634











Equity as of 31 Dec. 2013

1,660,572,426


166,057

-

407,289

1,968

(296,272)

279,042











Net loss for the year







(19,996)

(19,996)

Other comprehensive income for the year





26


26

Total comprehensive income





26

(19,996)

(19,970)











Warrant exercises

1,954,857


195

489




684

Share-based payment







1,782

1,782

Transfer of retained earnings



(489)



489

-











Equity as of 31 Mar. 2014

1,662,527,283


166,252

-

407,289

1,994

(313,997)

261,538

 

Notes

1.   Accounting policies
The interim report is prepared in compliance with International Accounting Standard No. 34 (IAS 34), "Interim Financial Reporting" and in accordance with the NASDAQ OMX Copenhagen's financial reporting requirements for listed companies.

There have been no changes in accounting policies used for the interim report compared to the accounting policies used in the preparation of Veloxis Pharmaceuticals' annual report for 2013.

©2012 PR Newswire. All Rights Reserved.